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Introduction
The neuromuscular junction (NMJ) disorders are often 
seen in the clinical practice of general neurologists and oth-
er specialists. The prevalence of myasthenia gravis (MG), 
the most common NMJ disorder is 1:10.000 inhabitants [1]. 
At the same time, the spectrum of diseases affecting neu-
romuscular transmission at the synapse level is wide. If the 
classical postsynaptic disorder like MG is easily diagnosed, 
the presynaptic one is often misinterpreted. The presynap-
tic NMJ disorder like the Lambert-Eaton myasthenic syn-
drome (LEMS) is rare. It is an idiopathic or paraneoplastic 
autoimmune disorder of the presynaptic nerve terminal of 
the NMJ transmission. The relation between patients with 
LEMS and MG is 1:10 [2]. At the same time, the establish-
ment of the correct diagnosis could lead to the search of the 
malignity when the last is at the treatable stage. 
LEMS is a rare condition with the main clinical manifes-
tation of skeletal muscular weakness, reduced reflexes and 
autonomic involvement. Specific clinical picture, laboratory 
and electrophysiological studies allow for early diagnosis, 
which is important as this syndrome is strongly associated 
with small cell lung cancer (SCLC) [3]. 
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Abstract
Background: Lambert-Eaton myasthenic syndrome (LEMS) is a rare disorder of the neuromuscular junction. Clinical features include proximal muscle 
weakness, markedly in the lower limbs, reduced deep tendon reflexes that can increase after exercise, and autonomic disturbances. The clinical picture 
as well as knowledge of the laboratory test that accompany LEMS will permit early recognition of the disease, that is crucial because it is often associated 
with malignancy, especially small cell lung cancer (SCLC). In this article we present a patient with proximal muscle weakness and typical changes on 
repetitive nerve stimulation, as well as a short literature review on the topic. 
Conclusions: The diagnosis of LEMS is usually made on clinical grounds. The diagnosis is confirmed by electrophysiological testing, main features including 
decrement response on slow repetitive nerves stimulation (3Hz), and an increment of more than 100% in CMAP amplitude after brief exercise, or high 
frequency repetitive stimulation (30-50 Hz). Immunological panel assay with positive P/Q-type VGCC antibody is strongly suggestive of LEMS. While 
symptomatic treatment with 3,4 – diaminopyridine is available, one of the main priorities is evaluation for underlying malignancies in these patients, 
the most common being SCLC. Evaluation of patients with LEMS and no known cancer should start with CT of the chest, abdomen and pelvis. Brain 
imaging is recommended if focal neurological signs are present. If the initial evaluation of the patient is negative, repeated screening for malignancy after 
6 months and up to two years is recommended. 
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P/Q-type voltage gaited calcium channels (VGCC) that re-
duce the amount of acetylcholine (Ach) released in the syn-
aptic cleft [4].
We present a typical Lambert-Eaton syndrome. 
A 58 year-old male, a truck driver, complaining of proxi-
mal muscle weakness and progressive gait disturbance (re-
quiring a cane for walking at first presentation) for 2 months. 
Upon admission he had as well dry mouth, hypohidrosis. 
The patient noticed that he could stand up with difficulties 
in the cabin of the car. He complained of low back pain and 
his family physician diagnosed him with radiculopathy. He 
received treatment with Dexamethasone 8 mg and NSAIDs 
for 5 days consecutively with no significant improvement.
The patient’s history is remarkable as he is a heavy smok-
er (138 pack-years, 60 cigarettes per day).  The patient also 
suffers from a mild diabetes mellitus, arterial hypertension, 
and hepatic steatosis. At clinical examination he had a blood 
pressure 130/80 mmHg on antihypertensive medications, 
heart rate 75 beats per minute, in sinus rhythm, respira-
tory frequency 18 per min, and a BMI – 39.1 that qualifies 
as obesity class 2. Neurological examination revealed de-
creased muscle strength on MRC scale 4/5 in all limbs, but 
with a 3/5 in proximal muscle groups. He hardly could stand 
up from sitting position and had decreased deep tendon 
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reflexes, which improved after exercise. The sensory dis-
turbances were suggestive of polyneuropathy with hypoes- 
thesia in “gloves and socks” distribution and segmental L5 
– S1 hypoesthesia. Neither pathological signs nor sphinc-
ter disturbances were found. Cerebellar tests were normal. 
Meningeal and elongation signs were negative.
MRI of the lumbar spine was performed that revealed 
intervertebral discs protrusions at the L2 – L3, L3 – L4, L5 
– S1 levels. 
Routine nerve conduction studies were performed which 
were within normal range.  On EMG with slow (3Hz) repeti-
tive nerve stimulation (RNS), decrement of 21% (fig. 1) was 
noted at rest, at the first examination, with a compound mus-
cle action potential (CMAP) increase of more than 100% in 
amplitude after isotonic exercise for 30 seconds (fig. 2). 
The history and physical examination of the patient, with 
proximal muscle weakness, increase in deep tendon reflexes 
after exercise, as well as increase of amplitude of more than 
100% on repetitive nerve stimulation after isometric con-
traction, lead to the idea of a presynaptic disorder [5]. Given 
the history of the patient being a heavy smoker and clinical 
and electrophysiological changes suggesting a presynaptic 
disorder, the presumption of Lambert-Eaton myasthenic 
syndrome was made.
Fig. 1.  Decrement of 21% at rest during slow (3 Hz) repetitive 
nerve stimulation of the left ulnar nerve.
Fig. 2.  Increment of more than 100% in CMAP amplitude 
following a 30 seconds isotonic exercise in the left ulnar nerve.
Computer tomography (CT) of the lungs was ordered to 
rule out neoplastic formations, and serological testing for 
specific antibodies was carried out. 
The malignancy workup including CT of the lungs (fig. 
3), oncological markers for CEA, PSA, CA 19-9 came back 
negative, while immunologic assay for anti VGCC anti-
bodies came positive for both type N and PQ (tab. 1) that 
further confirmed our suspicions of Lambert-Eaton myas-
thenic syndrome.
During admission, plasma exchange was initiated with 
mild improvement of symptoms. When the immunologic 
results for anti VGCC came positive, treatment with Pred-
nisone and Azathioprine was started to control the immune 
response, while 3,4-diaminopyridine was recommended for 
symptoms control. 
Fig. 3.  Lung CT without pathological changes.
Table 1
Immunologic assay for anti VGCC (type N and PQ)
Type N     20,9 Index  < 10
Type PQ   248,9 pmol/L  < 40
Discussion
Our patient addressed the first time for low back pain, 
and that remained his chief complaint even 2 months later 
after the initial episode, in spite of progressive weakness and 
difficulties in walking and getting up from a chair. 
The most common causes of low back pain are degenera-
tive disc disease, spondylosis, spinal stenosis, radiculopathy, 
and fractures. These mechanical conditions account for 
about 90% of cases in low back pain patients. Non-mechani-
cal causes may include myopathy, myelopathy, plexopathies, 
neuropathies, neoplasms, vascular, gastrointestinal, and 
genitourinary infections [6].
The history and physical examination revealed proximal 
weakness greater than distal. The most common neuromus-
cular disorders causing this pattern of weakness include 
myopathies, acute/chronic inflammatory demyelinating 
polyradiculoneuropathy such as Guillain-Barre syndrome 
or diabetic plexopathy, disorders of the neuromuscular 
junction, and forms of Spinal Muscular Atrophy, most 
common Type III (Kugelberg–Welander disease). The dif-
ferential diagnosis for neuromuscular junction disorders in-
cludes the most common post-synaptic disorders, MG and 
pre-synaptic disorders such as LEMS and botulism.
In our patient, back pain can be explained by the sequa-
lae of LEMS. The proximal weakness and weakness of the 
supporting structures of the spine and more prominent in 
the lower back, contributed to an over stress of the lower 
spine that resulted in low back pain [7]. 
LEMS is a rare condition which results from an autoim-
mune attack against voltage-gated calcium channels at the 
presynaptic motor nerve terminal [8]. It is the second most 
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common neuromuscular junction disorder. This causes an 
abnormality of acetylcholine release at the neuromuscu-
lar junction. In LEMS the number of Ach quanta released 
from the presynaptic membrane is reduced, despite normal 
amount of Ach vesicles, normal presynaptic concentra-
tion, and normal postsynaptic Ach receptors. Lambert and 
Elmqvist described the unique features of this condition 
with normal miniature endplate potential amplitude, dem-
onstrating normal postsynaptic sensitivity to acetylcholine 
and markedly reduced evoked endplate potential amplitude, 
suggesting a significant reduction in Ach release [9]. Ach 
release is increased by increasing calcium concentration but 
not potassium-induced depolarization. 
LEMS is an autoimmune disorder with autoantibodies 
directed against voltage-gated calcium channels (VGCC). 
VGCC is a large transmembrane protein with many subunits 
and is the target of the antibodies. These antibodies interfere 
with normal function of the VGCC, thus reducing the nor-
mal flux of calcium required for release of acetylcholine [8].
Typical age of onset is of 50 years or more and is charac-
terized by leg and/or general weakness, rarely muscle pain, 
arm weakness, diplopia and dysarthria [10]. Autonomic 
dysfunction such as xerostomia, hypohidrosis, blurred vi-
sion; constipation and orthostatic hypotension have been 
frequently observed [11]. Post exercise facilitation is anoth-
er distinctive feature and is characterized by increase of the 
deep tendon reflexes and muscular strength after exercise. 
Cranial nerves are usually spared [12]. Respiratory symp-
toms may occur [13, 14]. 
There are two major forms of LEMS: paraneoplastic and 
non-paraneoplastic. It is most commonly associated with 
small cell lung cancer (SCLC) especially in heavy smokers, 
more frequently in males than in females [15, 16]. 
Electrophysiological testing includes routine motor and 
sensory nerve conduction studies, high-frequency repeti-
tive nerve stimulation (RNS) and/or exercise testing that 
shows changes suggesting dysfunction of the presynaptic 
membrane in LEMS [17]. Needle electromyography is done 
to exclude motor neuron disease, and in selected patients, 
single fiber electromyography is performed as it is very sen-
sitive for neuromuscular junction disorders, but not specific 
for a presynaptic localization [18]. 
Routine motor and sensory nerve conduction studies 
should be performed in at least two nerves, CMAP ampli-
tudes usually are diffusely low or borderline, with normal 
latencies and conduction velocities. This response may in-
crease after brief exercise [18]. 
RNS and exercise testing is done by either high-frequen-
cy (30-50Hz) RNS or slow (2-3 Hz) RNS stimulation and 
brief, 10 seconds, exercise. Exercise testing is better toler-
ated by the patients and is preferable to fast RNS unless the 
patient can not cooperate. An increment greater than 40% 
is abnormal. Most patients with LEMS will have an incre-
ment greater than 100%. Any increment between 40 and 
100% is a sign of presynaptic disorder. Slow RNS (3Hz) may 
elicit a decremental response, however, after brief exercise, 
the baseline CMAP is significantly larger compared to pre-
exercise CMAP [5, 19]. This peculiarity was registered at 
our patient.
Needle electromyography is usually normal in LEMS, 
but the action potential may be unstable and of low ampli-
tude, sometimes polyphasic with normal or early recruit-
ment pattern [18, 20]. 
Single-fiber EMG may be performed, and changes will 
be consistent with a neuromuscular junction disorder, like 
increased jitter and blocking, but it cannot differentiate 
LEMS from other disorders of the neuromuscular junction 
[21, 22, 23].  Serologic panel should contain P/Q calcium 
channel antibodies, creatine kinase and paraneoplastic 
markers [4, 24]. 
Differential diagnose should be made with MG [12], my-
opathies [25] and motor neuron disease [26]. MG involves 
the ocular and bulbar muscles to a greater extent whereas in 
LEMS the proximal lower extremities are primarily affected. 
In motor neuron disease muscle atrophy, hyperreflexia and 
pathological signs are the prominent features in contrast to 
LEMS where these clinical signs are not present. Electro-
physiological and serological testing will differentiate from 
myasthenia gravis, myopathy or motor neuron disease.
Main priority in a patient with LEMS is to evaluate for 
malignancy that is found in about 50% of cases [27, 28]. 
In many patients, treatment of the underlying malignancy 
will improve the neurological symptoms.  The most com-
mon tumor associated with LEMS is small cell lung cancer, 
especially among smoking patients which are 50 years or 
older [27]. Other malignancies associated with LEMS are 
Hodgkin lymphoma [29, 6], and rarely atypical carcinoid 
[30], thymic neuroendocrine carcinoma [31], malignant 
thymoma [32], and neuroblastoma [33]. 
Evaluation of patients diagnosed with LEMS and no 
known cancer, should start with CT of the chest, abdomen 
and pelvis. Brain imaging is recommended if focal neuro-
logical signs are present.  If the initial evaluation of the pa-
tient is negative, repeated screening for malignancy after 6 
months is recommended. Evaluations should be repeated 
until at least 2 years if no cancer is found [34]. 
Patients with paraneoplastic LEMS have a shortened 
life expectancy because of the progression of the associated 
neoplasm. Survival is correlated with the stage of the disease 
at presentation. A longer survival was observed in patients 
with SCLC that developed LEMS, the last one representing 
an independent predictor of prolonged survival [34]. 
Patients with non-paraneoplastic LEMS may have a nor-
mal or almost normal life expectancy, although a minority 
may remain disabled. Most of the deaths were not caused by 
LEMS but they might be related to complications of gluco-
corticoid therapy. 
First line treatment in LEMS is 3,4 – diaminopyridine 
(3,4 – DAP) [35] that blocks the presynaptic voltage-gated 
potassium channels increase obtaining in result the release 
of ACh into the synaptic cleft. Long term immunosuppres-
sive treatment with prednisone and azathioprine, plasma 
exchange or IVIg help ameliorate the symptoms. However, 
the aggressive immune suppression can lead to immunolog-
ic suppression of tumor growth and in this case, it is up to 
the physician whether aggressive therapy is safe [34]. 
At our patient the search for a malignancy didn’t give an 
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indication of an underlying cancer. In spite of the fact that 
the patient is a heavy smoker we didn’t get evidence of a 
SCLC. We will repeat the investigations, including chest CT, 
3-6 months later. Treatment with azathioprine and cortico-
steroids slightly improved his condition.
Conclusions
LEMS is an acquired paraneoplastic or idiopathic dis-
order of the pre-synaptic membrane of the NMJ. Autoan-
tibodies directed against voltage-gated calcium channels 
located on the pre-synaptic membrane lead to a decrease 
in release of acetylcholine in to the synaptic cleft. Clinical 
features include proximal muscle weakness, markedly in 
the lower limbs, reduced deep tendon reflexes that can in-
crease after exercise, and autonomic disturbances. In about 
50% of cases LEMS is associated with small cell lung cancer. 
Electrophysiological testing is important in the diagnostics 
of LEMS, main features including decrement response on 
slow repetitive nerves stimulation (3Hz), and an increment 
of more than 100% in CMAP amplitude after brief exercise, 
or high frequency repetitive stimulation (30-50 Hz). Im-
munological assay for antibodies directed against voltage- 
gated calcium channels P/Q or N type has a high specificity 
and is confirmatory of LEMS when present. Symptomatic 
Treatment includes 3,4 – diaminopyridine (3,4 – DAP) and 
immunosuppression, with intensive monitoring for malig-
nancy, especially small cell lung cancer. 
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